Data Sheet 3_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 6_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Boxplots showing the differences in miR-21-5p and miR-16-5p levels across increasing AKI severity based on Kidney Disease: Improving Global Outcomes (KDIGO) grades. by Tamar J. van der Aart (22184206)

“…<p>Elevated miR-21-5p levels and decreased miR-16-5p levels correspond to greater AKI severity. …”

Image 1_Safety profile and efficacy of secukinumab in the treatment of autoimmune myasthenia gravis: a single-center retrospective study.jpeg by Shuangmei Zhang (1807303)

“…Limitations include small sample size and retrospective design, warranting validation in larger randomized trials.</p>…”

Data Sheet 1_Safety profile and efficacy of secukinumab in the treatment of autoimmune myasthenia gravis: a single-center retrospective study.pdf by Shuangmei Zhang (1807303)

“…Limitations include small sample size and retrospective design, warranting validation in larger randomized trials.</p>…”

Table_1_Successful treatment of refractory palmoplantar pustulosis by upadacitinib: report of 28 patients.DOC by Na Du (294594)

“…DLQI scores decreased from (12.55 ± 4.56) to (2.03 ± 1.13), also showing a statistically significant difference (p < 0.05). …”

Rising mercury consumption from blue foods in China balanced by a shift to lower-mercury choices by Wendy Wang (19812924)

“…Results show that despite per capita THg consumption rose gradually due to rising blue food consumption, there was a national shift toward low-THg blue foods driven by increased shrimp and decreased high-THg fish consumption. Coastal regions exhibited the highest THg consumption due to greater blue food consumption while Northwest China displayed high-THg preferences with low overall consumption. …”

Supplementary file 1_Tapered fiber probe-based optical cardiac pacemaker.docx by Yanzheng Xie (22596953)

“…Meanwhile, anatomical mapping demonstrated 1.7-fold greater photosensitivity in sinoatrial regions compared to ventricular myocardium. …”

Height and canopy measurements of native shrubs in southern California by Emma Underwood (22077698)

“…We identified four key findings: (1) shrub biomass increased with time since last fire and the proportion of resprouting species, and decreased with distance to coast and solar radiation; (2) species with the ability to resprout (obligate resprouter and facultative seeders) contributed greater biomass at all post-fire time periods and locations when compared with obligate seeders; (3) we found higher average biomass contributed by both obligate seeder and obligate resprouter species in plots closer to the coast than interior plots; and (4) fourth, we found a significant positive relationship between woody shrub richness and biomass. …”

Table 1_Deep brain stimulation for obsessive compulsive disorder leads to symptom changes of comorbid irritable bowel syndrome.docx by Mohamed A. Abdelnaim (16976001)

“…Future research using larger sample sizes should address whether the reductions are tied to the improvement of OCD symptoms or if DBS exerts positive effects on IBS independently of OCD symptoms.…”